{"id":543296,"date":"2021-05-14T16:32:02","date_gmt":"2021-05-14T16:32:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=543296"},"modified":"2021-05-14T16:32:02","modified_gmt":"2021-05-14T16:32:02","slug":"aplastic-anemia-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-pfizer-regeneron-pharmaceuticals-regen-biopharma-omidubicel-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/aplastic-anemia-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-pfizer-regeneron-pharmaceuticals-regen-biopharma-omidubicel-and-others_543296.html","title":{"rendered":"Aplastic Anemia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Pfizer, Regeneron Pharmaceuticals, Regen BioPharma, Omidubicel and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1620963733.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Aplastic Anemia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Pfizer, Regeneron Pharmaceuticals, Regen BioPharma, Omidubicel and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1620963733.jpeg\" alt=\"Aplastic Anemia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Pfizer, Regeneron Pharmaceuticals, Regen BioPharma, Omidubicel and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Aplastic Anemia Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Aplastic Anemia<\/strong> is a medical condition that damages stem cells in a person&rsquo;s bone marrow. These cells are responsible for making red blood cells, white blood cells, and platelets, which are vital to human health. A rare and serious condition, aplastic anemia can develop at any age. It can occur suddenly, or it can come on slowly and worsen over time. It can be mild or severe. Treatment for aplastic anemia might include medications, blood transfusions or a stem cell transplant, also known as a bone marrow transplant. The most common cause of aplastic anemia is from your immune system attacking the stem cells in your bone marrow. Other factors that can injure bone marrow and affect blood cell production include: Radiation and chemotherapy treatments, exposure to toxic chemicals, use of certain drugs, autoimmune disorders, a viral infection and unknown factors.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/aplastic-anemia-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Aplastic Anemia Pipeline<\/a><\/strong><strong> Insight, 2021<\/strong>&rdquo; report provides comprehensive insights about <strong>10+ companies and 15+ pipeline drugs<\/strong> in Aplastic Anemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the Aplastic Anemia Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Pfizer<\/li>\n<li>Regeneron Pharmaceuticals<\/li>\n<li>Regen BioPharma<\/li>\n<li>Omidubicel<\/li>\n<li>Cellenkos<\/li>\n<li>Hemogenyx<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/aplastic-anemia-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/aplastic-anemia-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Aplastic Anemia report covers around 15+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase III and<\/li>\n<li>Mid-stage products (Phase II and<\/li>\n<li>Early-stage products (Phase I\/II and Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/aplastic-anemia-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Aplastic Anemia Therapies<\/a> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>PF-06462700<\/li>\n<li>REGN7257<\/li>\n<li>HemaXellerate<\/li>\n<li>Gamida Cell<\/li>\n<li>CK-0801<\/li>\n<li>Hu PHEC<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/aplastic-anemia-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/aplastic-anemia-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Current Aplastic Anemia Treatment Scenario and Aplastic Anemia Emerging Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>How many companies are developing Aplastic Anemia drugs?<\/li>\n<li>How many Aplastic Anemia drugs are developed by each company?<\/li>\n<li>How many emerging drugs are in mid-stage, and late-stage of development for Aplastic Anemia?<\/li>\n<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Aplastic Anemia therapeutics?<\/li>\n<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?<\/li>\n<li>What are the clinical studies going on for Aplastic Anemia and their status?<\/li>\n<li>What are the key designations that have been granted to the emerging drugs?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/aplastic-anemia-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/aplastic-anemia-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Aplastic Anemia: Overview<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Aplastic Anemia&ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">Aplastic Anemia Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">PF-06462700: Pfizer<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Drug Name: Company Name<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase I\/II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Omidubicel: Gamida Cell<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Pre-clinical and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Hu-PHEC: Hemogenyx<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Aplastic Anemia Key Companies<\/p>\n<p style=\"text-align: justify;\">Aplastic Anemia Key Products<\/p>\n<p style=\"text-align: justify;\">Aplastic Anemia- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Aplastic Anemia- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Aplastic Anemia- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Aplastic Anemia Analyst Views<\/p>\n<p style=\"text-align: justify;\">Aplastic Anemia Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: https:\/\/www.delveinsight.com\/sample-request\/aplastic-anemia-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;<\/strong><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=aplastic-anemia-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-pfizer-regeneron-pharmaceuticals-regen-biopharma-omidubicel-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/aplastic-anemia-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/aplastic-anemia-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/aplastic-anemia-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=aplastic-anemia-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-pfizer-regeneron-pharmaceuticals-regen-biopharma-omidubicel-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aplastic Anemia Pipeline Aplastic Anemia is a medical condition that damages stem cells in a person&rsquo;s bone marrow. These cells are responsible for making red blood cells, white blood cells, and platelets, which are vital to human health. A rare &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/aplastic-anemia-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-pfizer-regeneron-pharmaceuticals-regen-biopharma-omidubicel-and-others_543296.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-543296","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=543296"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/543296\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=543296"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=543296"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=543296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}